Transaction #1329 · Form 4 · 0001438133-25-000177
TANDEM DIABETES CARE INC · Exercise / conversion · Common Stock
TANDEM DIABETES CARE INC · Transacted October 15, 2025 · Filed October 17, 2025
What does this filing report?
An SEC Form 4 filing for TANDEM DIABETES CARE INC records an exercise / conversion involving Common Stock on October 15, 2025. The reported quantity was 3,636. The filing date is October 17, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- TANDEM DIABETES CARE INC
- Company CIK
- 0001438133
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 3,636
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 23,685
- Ownership description
- Not reported
- SEC acceptance time
- Oct 17, 2025, 4:21 PM EDT
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Kyrillos Jean-Claude ↗
EVP & Chief Operating Officer
CIK 0001804186
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.
- F2
- Awarded on July 15, 2024 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).
- F3
- Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.
- F4
- RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 7/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.